Fate Therapeutics

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Fate Therapeutics reports strong financials, advances innovative CAR cell therapies

Fate Therapeutics reported strong financial performance with a focus on advancing key programs and innovative CAR NK and CAR T-cell products.
The company faces challenges in managing costs post-collaboration termination and navigating increased research and development expenses.
Opportunities lie in advancing IND submissions, exploring novel therapy combinations, and enhancing transparency through data disclosures and collaboration.
Overall, Fate Therapeutics showcases strength in leveraging proprietary platforms for differentiated therapies and commitment to advancing next-gen CAR T-cell products.

Fate Therapeutics reports robust Q1 revenue growth and strategic focus

Fate Therapeutics reported strong Q1 revenue growth but faces challenges with workforce reduction and disclosure commitments
The company's financial position is robust, with a focus on advancing key CAR NK and CAR T-cell programs in 2023
Opportunities lie in exploring autoimmune applications, biomarker evaluation, and ADR technology superiority for future growth
Navigating FDA requirements and study design complexities remain key challenges for program advancement

Fate Therapeutics navigates revenue challenges, advances CAR cell programs

Fate Therapeutics faced revenue challenges in Q2 but maintained a strong financial position with significant cash reserves.
Progress in advancing CAR-NK and CAR-T cell programs signals potential growth opportunities in the oncology space.
Clear guidance on operating expenses and strategic IND submissions demonstrate a proactive approach to future growth.
Addressing revenue diversification, cost management, and effective clinical development will be key focus areas for sustained success.

Fate Therapeutics advances innovative cell therapies amidst financial stability

Fate Therapeutics demonstrated strong progress in product development and financial management, positioning them as a leader in innovative cell therapies.
While facing challenges in revenue dynamics and managing expenses, the company has opportunities to drive value through upcoming milestones and pioneering treatment approaches.
Clear communication, strategic partnerships, and a focus on clinical proof of concept will be crucial for Fate Therapeutics to navigate the competitive landscape and capitalize on opportunities for growth.
The company's commitment to advancing novel therapies in oncology and autoimmunity underscores their dedication to addressing unmet medical needs and shaping the future of patient care.

Fate Therapeutics reports solid financials, eyes autoimmune therapy expansion

Fate Therapeutics showcases strong financial position but faces expense challenges.
Their off-the-shelf cell therapy programs exhibit promising efficacy and safety profiles.
Opportunities lie in expanding clinical investigations and exploring autoimmune indications.
Challenges include high operating expenses and the need for therapy differentiation.

Fate Therapeutics excels in autoimmune therapy innovation amidst financial stability

Fate Therapeutics showcased strong performance in Q1 2024 with promising data from FT819 and FT522 programs in autoimmune diseases.
While facing high operating expenses, the company maintains financial stability and aims for continued growth and innovation in cellular therapy.
Challenges in differentiation and clinical translation are met with opportunities for expanded indications and novel treatment approaches in autoimmune settings.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Graphite Bio

Century Therapeutics

Third Harmonic Bio Inc

Vera Therapeutics

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)

LOS ANGELES--( BUSINESS WIRE )--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fate Therapeutics, Inc. (“Fate” or “the Company”) (NASDAQ: FATE) for violations of the securities laws.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Fate Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Fate Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Tcr2 Therapeutics

Layoffs have been making headlines so far in 2023, even though we're just a few days into the new year. That's true even for gene-editing stocks.

CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC

FATE decides not to continue its collaboration and option agreement with Janssen. The company also conducts a strategic review.

FATE To End Janssen Deal and Prioritize Pipeline Development

Fate Therapeutics (NASDAQ: FATE ) stock is falling hard on Friday after the company announced the termination of its collaboration with Janssen Biotech. Janssen was seeking to continue its collaboration with Fate Therapeutics with revised terms and conditions.

Why Is Fate Therapeutics (FATE) Stock Down 62% Today?

Tesla

The Nasdaq Composite once again is underperforming the rest of the market.

Tesla Falls Again, but This Nasdaq Stock Is Truly Plunging

Shares of Fate Therapeutics Inc. FATE, -1.08% plunged 56.8% in premarket trading, putting them on track for a record one-day selloff, after the biopharmaceutical company announced the termination of its collaboration with Janssen Biotech Inc. and announced job cuts. The company said it had declined Janssen's proposal to continue the collaboration on “revised terms and conditions.

Fate Therapeutics stocks heads for record selloff after Janssen collaboration terminated and job cuts

Fate Therapeutics says it will reduce its work force by about 220 employees and discontinue clinical development of several cell programs.

Fate Stock Sinks. Analysts Downgrade Shares on End to Janssen Collaboration and Layoffs.

Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents & Receivables; 3-year Operational Runway Provided through Pipeline Prioritization and Expense Reduction

Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives

Iovance Biotherapeutics

Sabine Royalty Trust

After ending 2022 on a low note, U.S. market indexes continued to sink on Thursday morning after jobs data showed the labor market is still hot despite the Federal Reserve's attempts to curb inflation. According to CNBC, the ADP private payrolls report indicated employers added 235,000 jobs in December, which was higher than economists' estimates.

3 Graham's Lost Formula Picks to Consider for the New Year

Fate Therapeutics (FATE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Strength Seen in Fate Therapeutics (FATE): Can Its 9.3% Jump Turn into More Strength?

Shares have fallen by over 80% during the past 12 months. iPSC-derived NK cell programs sport advantages such as streamlined manufacturing, optimization and convenient administration.

Fate Therapeutics: iPSC Pioneer A Buy For Long-Term Investors

Fate Therapeutics (FATE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Fate Therapeutics (FATE) Loses -50.54% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Arvinas Inc

Axsome Therapeutics

Denali Therapeutics

Chart Industries

Karuna Therapeutics Inc

Rocket Pharma

Analysts say a tough 2022 has left these small-cap stocks priced for outperformance in the new year and beyond.

7 Best Small-Cap Stocks to Buy for 2022 and Beyond

Interim Phase 1 Data of FT576 BCMA-targeted Product Candidate Show Clinical Activity in Initial Single-dose Escalation Cohorts as Monotherapy and in Combination with Daratumumab

Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting

FT819 Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Engineered Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus

Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting

Fate Therapeutics was one of my favorite investments, however, I made the haunting mistake of closing the position only to see the ticker nearly triple. This time will be different. FATE has lost roughly 60% over the past twelve months. I believe the ticker is trading near a reasonable valuation for its upside potential. I reveal my strategy.

Fate Therapeutics: Returning To The Ticker That Changed The Way I Invest

SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the following upcoming investor conferences:

Fate Therapeutics to Present at Upcoming Investor Conferences

Fate Therapeutics, Inc. (NASDAQ:FATE ) Q3 2022 Earnings Conference Call November 3, 2022 5:00 PM ET Company Participants Scott Wolchko - President & Chief Executive Officer Ed Dulac - Chief Financial Officer Bob Valamehr - Chief Research & Development Officer Conference Call Participants Tazeen Ahmad - Bank of America Michael Yee - Jefferies Tyler Van Buren - Cowen Yigal Nochomovitz - Citigroup Michael Schmidt - Guggenheim Securities Daina Graybosch - SVB Securities Peter Lawson - Barclays Gil Blum - Needham Operator Welcome to the Fate Therapeutics Third Quarter 2022 Financial Results Conference Call. At this time, all participants are in listen-only mode.

Fate Therapeutics, Inc. (FATE) Q3 2022 Earnings Call Transcript

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 7.53% and 2.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Fate Therapeutics (FATE) Reports Q3 Loss, Lags Revenue Estimates

FT596+R Enrollment Ongoing in Three-dose Escalation Cohort for R/R BCL; Activating Community Sites for Investigation of FT596+R-CHOP in Newly-diagnosed Patients with Aggressive BCL

Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress

Clinical Presentations to Include Initial Clinical Data of FT576 BCMA-targeted CAR NK Cell Product Candidate for Multiple Myeloma and FT819 CD19-targeted CAR T-cell Product Candidate for B-cell Lymphoma

Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the 2022 ASH Annual Meeting

Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Fate Therapeutics (FATE) to Report a Decline in Earnings: What to Look Out for

SAN DIEGO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will host a conference call and live audio webcast on Thursday, November 3, 2022 at 5:00 PM ET to report its third quarter 2022 financial results and provide a corporate update.

News for Fate Therapeutics Stock (FATE)